T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

Abstract CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell infiltrate. Here, we show that pre-treatment vaccinat...

Full description

Bibliographic Details
Main Authors: Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy Lloyd, Vitalijs Ovcinnikovs, Gijs G. Zom, Renoud J. Marijnissen, Christianne Groeneveldt, Lisa Griffioen, Gerwin G. W. Sandker, Sandra Heskamp, Sjoerd H. van der Burg, Tsolere Arakelian, Ferry Ossendorp, Ramon Arens, Janine Schuurman, Kristel Kemper, Thorbald van Hall
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-44308-6

Internet

https://doi.org/10.1038/s41467-023-44308-6

Similar Items